MA50899B1 - Composés utiles pour l'inhibition de cdk7 - Google Patents

Composés utiles pour l'inhibition de cdk7

Info

Publication number
MA50899B1
MA50899B1 MA50899A MA50899A MA50899B1 MA 50899 B1 MA50899 B1 MA 50899B1 MA 50899 A MA50899 A MA 50899A MA 50899 A MA50899 A MA 50899A MA 50899 B1 MA50899 B1 MA 50899B1
Authority
MA
Morocco
Prior art keywords
compounds useful
cdk7 inhibition
cdk7
inhibition
novel
Prior art date
Application number
MA50899A
Other languages
English (en)
Other versions
MA50899A (fr
Inventor
David Andrew Coates
David Michael Remick
Carlos Montero
Bharvin Kumar Rameschandra Patel
Vipin Yadav
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Priority claimed from PCT/US2018/060025 external-priority patent/WO2019099298A1/fr
Publication of MA50899A publication Critical patent/MA50899A/fr
Publication of MA50899B1 publication Critical patent/MA50899B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux inhibiteurs de cdk7 et des compositions pharmaceutiques associées : (i), ou un sel pharmaceutiquement acceptable de ceux-ci.
MA50899A 2017-11-16 2018-11-09 Composés utiles pour l'inhibition de cdk7 MA50899B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382778 2017-11-16
PCT/US2018/060025 WO2019099298A1 (fr) 2017-11-16 2018-11-09 Composés utiles pour l'inhibition de cdk7

Publications (2)

Publication Number Publication Date
MA50899A MA50899A (fr) 2020-09-23
MA50899B1 true MA50899B1 (fr) 2022-10-31

Family

ID=60484312

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50899A MA50899B1 (fr) 2017-11-16 2018-11-09 Composés utiles pour l'inhibition de cdk7

Country Status (2)

Country Link
AR (1) AR113817A1 (fr)
MA (1) MA50899B1 (fr)

Also Published As

Publication number Publication date
MA50899A (fr) 2020-09-23
AR113817A1 (es) 2020-06-17

Similar Documents

Publication Publication Date Title
JOP20200122B1 (ar) مركبات مفيدة لتثبيط cdk7
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
MA42339A1 (fr) Modulateurs du récepteur farnésoïde x
MA46337A (fr) Composé de pyridine
EP4249071A3 (fr) Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
MA42776B1 (fr) Composés utiles pour l'inhibition du ror-gamma-t
MY202753A (en) Griseofulvin compound and pharmaceutical use thereof
EA201992542A1 (ru) Фармацевтическая композиция для местного применения, содержащая, по меньшей мере, амитриптилин, для лечения периферической нейропатической боли
MX376202B (es) Compuestos de tiofeno condensado utiles como inhibidores de napi-iib.
MD4010330T2 (ro) Derivați ai chinolinei ca inhibitori ai protein kinazei
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
PH12021550258A1 (en) Cdk8/19 inhibitors
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain
JOP20210226A1 (ar) تركيبة صيدلانية تشتمل على مركب مشتق بنزيميدازول
MA41311B1 (fr) Peptides antagonistes du cgrp
MA44383B1 (fr) Un derivé de 4-(3-pyrazolylamino)-benzimidazole en tant qu'inhibiteur de jak1 pour le traitement du cancer
WO2020065090A3 (fr) Traitement de tauopathies associées à une démence
MX394259B (es) Compuestos inhibidores de tirosina cinasa de bruton (btk)
EA202090930A1 (ru) Соединения, пригодные для ингибирования cdk7
MX385475B (es) Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa
JOP20180070B1 (ar) مثبطات إنزيم كيناز بروتين يتفاعل مع مستقبل 1
EA202090241A1 (ru) Новые гетероциклические соединения как ингибиторы cdk8/19